News & Analysis on the Clinical Development and Manufacture of Large Molecule Drugs
DISPATCHES FROM AAPS 2014
Lack of funding is threatening development of a nasal spray vaccine shown to provide long-term protection for non-human primates against the Ebola virus, the lead researcher told this publication in an exclusive interview.
Like the US and EU, China’s SFDA is looking to ensure that approved biosimilars are proven to be similar to their reference drugs, according to an unofficial translation of the guideline by BioCentury.
Bristol-Myers Squibb’s focus on immuno-oncology will result in three out of four drugs in its portfolio being biologics by 2019, according to the CFO.